Literature DB >> 7270460

Dobutamine in chronic ischemic heart failure: alterations in left ventricular function and coronary hemodynamics.

R Bendersky, K Chatterjee, W W Parmley, B H Brundage, T A Ports.   

Abstract

Changes in cardiac performance and coronary hemodynamics were evaluated during dobutamine infusion in patients with chronic heart failure associated with ischemic heart disease. At the maximal administered dose (10 micrograms/kg per min) cardiac index increased by 54 percent and stroke work index by 65 percent, indicating improved left ventricular function. Coronary sinus flow and myocardial oxygen consumption increased concomitantly, but myocardial lactate production occurred in only one of eight patients. These findings suggest that improved left ventricular function with dobutamine is associated with increased myocardial oxygen consumption; however, overt myocardial ischemia occurs infrequently.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7270460     DOI: 10.1016/0002-9149(81)90087-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Inotropic agents in the treatment of cardiogenic shock.

Authors:  H S Mueller
Journal:  World J Surg       Date:  1985-02       Impact factor: 3.352

2.  Additive positive inotropic effects of milrinone, ouabain and calcium in diseased human ventricular myocardium.

Authors:  L Brown; M Näbauer; E Erdmann
Journal:  Klin Wochenschr       Date:  1986-08-01

3.  Effect of dobutamine on left ventricular relaxation and filling phase in patients with ischemic heart disease and preserved systolic function.

Authors:  R Zeppellini; R Bolognesi; A Javernaro; R De Domenico; M Libardoni; D Tsialtas; D Piovan; R Padrini; F Cucchini
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

Review 4.  Newer positive inotropic agents in the treatment of chronic cardiac failure. Current status and future directions.

Authors:  K T Weber; S K Gill; J S Janicki; C S Maskin; M C Jain
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.